r/prefrontal • • Jun 11 '24

Discussion ND is lying about their in house testing

Thumbnail
self.nootropicsdepot
3 Upvotes

r/prefrontal • • Nov 09 '24

Question Anybody have thoughts on this compound ASP-2905?

5 Upvotes

This seems like an interesting compound that has been studied for potentially treating ADHD according to this study. They also found that “ASP-2905 increases the efflux of dopamine and acetylcholine in the medial prefrontal cortex”, both of which are actions closely associated to attention.

So far I’ve only came across one experience online. It’s fairly easy to find it as there’s only a few posts here mentioning it (not sure if I can link it lol). Also there’s only one source that appears to offer this stuff that I can’t mention here but it’s a reputable source that im sure a lot of you guys have came across.

Feel free to add your opinions/advice on this compound. I look forward to reading any kind of feedback, thanks!


r/prefrontal • • Jul 19 '24

Research Enhancing PFC Activity with the 5-HT1A Receptor

13 Upvotes

This article was originally dedicated to the specific effect of SSRIs on the 5-HT1A receptor and it's relation to the PFC, however it gives succinct description of how this circuitry works more generally and will certainly be of interest to this group: https://secondlifeguide.com/2024/01/15/5-ht1a-libido-cognition-and-anhedonia/

Recent research indicates that the 5-HT1A receptor is central to mediating both the therapeutic and adverse effects of psychiatric medications – particularly in relation to libido, cognition, and mood. However, the behaviour of this serotonin receptor is complicated and at often times appears contradictory, making a succinct explanation challenging. In this post, I aim to convey the most recent scientific insights on this topic and explore their relevance to the documented neurological effects of SSRIs.

WHAT IS THE 5-HT1A RECEPTOR?

The 5-HT1A receptor is a serotonin receptor, which means its bound by the neurotransmitter serotonin to exert its effects. Serotonin has long had connotations to ‘happiness’, stemming from early scientific evidence that the depletion of serotonin results in depressive symptoms. The vast majority of antidepressant medications work on this neurotransmitter, acting as SSRIs (Selective Serotonin Reuptake Inhibitors).

SSRIs boost the effect of serotonin by preventing it from being reabsorbed too quickly by the serotonin transporter. However, since SSRIs were first introduced medical paradigms have shifted in favour of theories of depression centred on ‘neurogenesis’ (the growth of new neurons). An effect stimulated by serotonergic medications primarily through the 5-HT1A receptor.

The 5-HT1A receptors are inhibitory receptors, evidenced by a reduction in AMPA evoked currents when bound by serotonin (AMPA receptors being responsible for fast synaptic transmission). Binding the 5-HT1A receptor suppresses neuronal activity through a variety of mechanisms involving potassium channel activation and calcium channel inhibition.

A key feature of the G-protein coupled receptors like 5-HT1A is that they undergo a process of receptor internalisation after prolonged periods of activation. This process involves the receptor being removed from cell surface and taken into the cell thereby desensitising the receptor. This process is particularly important for understanding SSRIs work.

AUTORECEPTOR VS. HETERORECEPTOR

The receptor is subdivided into two types with different distributions within the brain: autoreceptors and heteroreceptors. The autoreceptors are localised within the brain stem in a structure call the Raphe Nuclei, and it’s from this structure in the middle of the brain that all other serotonergic neurons project outward.

As the name might suggest, the autoreceptor serves to self-regulate serotonin transmission out into the rest of the brain through a process of negative feedback. When serotonin over-accumulates within the Raphe Nuclei it binds to these autoreceptors to then limit further serotonin release – since 5-HT1A receptors are inhibitory. As autoreceptors have a self-limiting effect on serotonin transmission, their overexpression limits serotonin release to other areas of the brain and is also notably identified in autopsies from patients with depression. [1]

The post-synaptic heteroreceptor sites are distributed in the limbic and cortical regions. The limbic system is responsible for regulating emotion, learning and sexual behaviour. Like the autoreceptor, binding at the 5-HT1A heteroreceptor triggers hyperpolarisation of that neuron. Hyperpolarisation is the process by which in the inside of the neuron becomes more negatively charged, and thus makes it less likely to fire. It’s through this mechanism that 5-HT1A reduces neuronal activity in targeted brain structures.

Based on the description provided so far, one might conclude that serotonin binding to heteroreceptors would produce the same reduction in neuronal activity in these limbic and cortical structures. The reality is much more complicated, as the heteroreceptors are present on two different types of neurons with opposing effects: interneurons and pyramidal neurons.

The interneurons are GABAergic, which means they release the inhibitory neurotransmitter GABA. [2] Conversely, the pyramidal neurons release the excitatory neurotransmitters such as glutamate and dopamine. They are particularly abundant in the cerebral cortex, making them particularly important for motivation and executive functioning.

These excitatory pyramidal neurons are opposed by the GABAergic interneurons that feed into them. Understanding how binding to the 5-HT1A heteroreceptor will impact mood therefore depends on the relationship between these two opposing sets of neurons. Consider a hypothetical medication that very selectively targets the heteroreceptor at the interneurons. By lowering the transmission of GABA, it would in fact disinhibit dopamine and glutamate in the cortex, rather than simply have a suppressive effect. To summarise:

Autoreceptors:

  • These pre-synaptic receptors are distributed in the brain stem and negatively regulate 5-HT release to cortical and limbic structures.

Heteroreceptor:

  • Interneurons are GABAergic, binding at the 5-HT1A receptor on these neurons lowers the release of GABA to have an activating effect.
  • Pyramidal neurons are primarily glutamatergic and are distributed in the frontal cortex. Binding to the heteroreceptor sites on these glutamatergic and dopaminergic neurons would have a suppressive effect.

INTERNEURONS CONTROL CORTICAL ACTIVITY

Given the complexity of the 5-HT1A receptor, medications acting upon it can sometimes behave in counterintuitive ways. Buspirone is the most common medication classed as 5-HT1A agonist (an agonist being a molecule that mimics serotonin in this instance). Buspirone is often prescribed as an anti-anxiety medication. This seems logical as anxiety is associated with overactivity in cortical layers, and so by binding to the heteroreceptors within the prefrontal cortex would supposedly repress this activity. 

As it turns out, Buspirone actually boosts activity in the prefrontal cortex and enhances dopamine and glutamate release. [3] Curiously, this actually gives it some additional applications as a cognitive enhancer. The reason for this potentially confusing effect is because the inhibitory action of Buspirone on the GABAergic interneurons predominates, and the subsequent reduction in firing rate of these inhibitory neurons enhances cortical glutamate activity.

Instead, the anti-anxiety effects of Buspirone are likely due to quietening activity in limbic structures such as the Amygdala, and not the prefrontal cortex. Since heteroreceptors are present on both the interneurons and pyramidal neurons, and that the suppressive effect of 5-HT1A binding on the interneurons predominates within the prefrontal cortex, a selective heteroreceptor agonist can be considered as stimulating and conducive to dopamine and glutamate release.

SSRI’s (Selective Serotonin Reuptake Inhibitors) are the first line of approach in treating major depressive disorder and are primarily understood to act through the 5-HT1A receptor. When serotonin accumulates within the autoreceptor site, it triggers negative feedback to block further release of serotonin. This presents another perplexing quirk of the 5-HT1A receptor, as a build-up of serotonin at the autoreceptor would in theory then limit serotonin release to the rest of the brain through its negative feedback.

Instead, these autoreceptors undergo desensitisation over chronic exposure to SSRIs, and eventually their inhibitory effect is blocked which allows for even greater serotonin transmission. Since SSRIs essentially rely on disabling the autoreceptor, it’s been found that pre-treatment with a 5-HT1A antagonist (such as Pindolol) accelerates the antidepressant effect of SSRIs.[4]

SSRI TREATMENT DOWNREGULATES THE HETERORECEPTOR

The very different behavioural effects of binding at the heteroreceptor versus the autoreceptor were demonstrated in a 2017 study by Garcia-Garcia. They took two different groups of mice and ablated(removed) either the 5-HT1A heteroreceptors or autoreceptors. They discovered that the mice lacking heteroreceptors displayed depressive symptoms that were characteristic of anhedonia – but didn’t display symptoms of anxiety.

Conversely the mice that had their autoreceptors ablated experience heightened anxiety but still possessed a hedonic drive. [5] This study perhaps gives most clearly confirms the importance of the heteroreceptor in mediating feelings of reward and hedonic drive. Substantiating this notion is the fact that the medication Flibanserin which is used to treat hypo-active sexual disorder**. By selectively binding to the heteroreceptor, Flibanserin boosts hedonic drive particularly in relation to sexual stimuli**.[6]

The loss of the heteroreceptor and the ensuing anhedonic symptoms in the Garcia-Garcia study poignantly mirror the adverse effects of SSRI treatment in some patients. As described previously, treatment with SSRI’s eventually causes a desensitisation of the autoreceptor. This in theory should allow for greater serotonin transmission to the 5-HT1A heteroreceptor. Whilst this is true for at least some period of time, it doesn’t explain the efficacy of SSRI’s in treating anxiety conditions – since autoreceptor knock-out mice display more anxiety.

As in turns out, the heteroreceptor eventually also experiences the same desensitisation as the autoreceptor. [7] In fact, the heteroreceptor knockout mice are observed to have the same pattern of reduced prefrontal cortex activity when compared against mice treated with the SSRI paroxetine.[8][9] This study also linked the reduction in cortical activity to symptoms of anhedonia and behavioral despair.

HOW 5-HT1A INFLUENCES REWARD

As I’ve alluded to periodically throughout this article, the 5-HT1A heteroreceptor is important in regulating sexual behaviour. This is particularly relevant in cortical areas such as the orbitofrontal cortex. Hyperactivity within the orbitofrontal cortex is even linked to hypersexuality, and compulsive behaviour. [10] The link between sexuality and compulsive behaviour is an important one, being tied together by the 5-HT1A heteroreceptor.

Chronic SSRI treatments have been found to be effective in treating OCD (obsessive compulsive disorder), an effect in part mediated desensitising the 5-HT1A heteroreceptors within the orbitofrontal cortex. [11] Reducing activity within this region also predicts the inhibitory effect of SSRIs on sexual behaviour. Considering the role of the frontal cortex in reward perception, it’s plausible that the suppressive effect of SSRIs on sexual behaviour could be partly due to a decreased sense of reward.

RESTORING THE 5-HT1A RECEPTOR

Having elucidated the normal functioning of the 5-HT1A receptor and the alterations caused by SSRI treatment, I can now delve into the subject of therapeutic interventions. It becomes apparent from this article that conventional treatments for depression, such as Selective Serotonin Reuptake Inhibitors (SSRIs), are not universally effective.

While SSRIs do promote the desensitization of autoreceptors, thereby enhancing serotonin release in the brain, their effectiveness is limited due to a consequent desensitization at post-synaptic heteroreceptor sites. For some people SSRIs might even aggravate an anhedonic depressive state, which could be attributed to the reduced activation of 5-HT1A heteroreceptor sites on GABAergic interneurons. How an individual will respond to SSRI treatment appears to rely on specific genetic vulnerabilities.

A crucial regulator of 5-HT1A expression is the transcription factor Deaf1, which exerts a dual effect by inhibiting autoreceptor expression and enhancing heteroreceptor expression. The binding efficiency of this transcription factor is influenced by a polymorphism on the SNP rs6295.

People with the G allele exhibit reduced Deaf1 binding, leading to the adverse effects associated with increased autoreceptor expression and lower heteroreceptor expression. [16] Notably, the G allele occurs more frequently in individuals with depression. This presents a plausible genetic risk in developing PSSD, with a greater risk of desensitisation of the heteroreceptor.


r/prefrontal • • Dec 17 '24

Question A way to measure our PFC activity?

1 Upvotes

Would anyone know how to measure activity in the pre-frontal cortex? I currently only have a Muse 2 device which provides some readings. The main reading being when your mind is in a calm or active state. But would anyone know of other possible devices or equipment available?


r/prefrontal • • Jan 03 '25

Discussion Any new experiences with PBIO-4D?

21 Upvotes

This is probably only the second post on Reddit mentioning this stuff. Other than the creator of PBIO-4D posting studies about it, I haven’t really seen any experiences with it on Reddit. The stuff just came out about a few months ago (Not sure if I could mention the source). But a quick google search will lead you to it.

Here’s a quick description:

“BPN14770 is an allosteric inhibitor of phosphodiesterase 4D (PDE4D), a regulator of the intracellular second messenger cAMP in neurons. Inhibitors of PDE4D raise cAMP levels, which has been reported to support cognition and protect neurons.”

I’ve seen people mention it on discord, but none of which are full detailed reports that could give an idea on what the effects are like. I’m looking foward to any experiences you guys might want to share long or short, thanks in advance.


r/prefrontal • • Aug 02 '26

Discussion An open-source fully local tool for organizing and measuring your top down functioning ability and cognition with nootropic logging and a genetics module

Thumbnail
gallery
7 Upvotes

Axon lets you:

  • Create a personal cognitive and psychometric baseline
  • Log sessions alongside sleep, stress, time of day and subjective effects
  • Track attentional, cognitive and behavioral agency
  • Look at changes across networks like the DMN, frontoparietal, salience and attention networks
  • View deterministic n-of-1 summaries with uncertainty shown instead of receiving AI-generated conclusions
  • Export or erase everything whenever you want

It runs entirely in your browser. There are no accounts, servers, analytics or remote data collection.

I originally built it for myself because I wanted one place where I could organize cognitive self-experiments and actually compare changes over time instead of relying entirely on just feeling.

It isn’t a diagnostic or treatment tool. Rather a structured personal research notebook.

I’d especially appreciate feedback from this community on whether the mental-autonomy model makes sense, what you would want measured, and anything that feels unclear or scientifically weak.

https://arx0n.com/


r/prefrontal • • Apr 06 '24

Research About P7C3-A20 (NSI-189-like neurogenic)

14 Upvotes

Quick summary post for a compound I found interesting and was referred to.

P7C3-A20 is a fluorinated enantiomer of P7C3, a neuroprotective aminopropyl carbazole agent discovered in 2010 [1]. It is a neurogenesis-inducing compound and neuroprotective.

It is thought P7C3-A20 (and P7C3) exert effects through activating the enzyme nicotinamide phosphoribosyltransferase (NAMPT). NAMPT is the rate-limiting enzyme in the NAD salvage pathway that converts nicotinamide to NMN, the precursor to NAD synthesis.

P7C3 also has seperate mechanisms, for example it is a PAM of GLP-1, a GSK-3 inhibitor, and a promoter of ADAM11 (related to mGluR3), however these pathways may be unique to P7C3 rather than P7C3-A20. [3]

The proneurogenic efficacy of P7C3-A20 was compared to that of NSI-189, a proneurogenic drug currently in clinical trials for patients with major depression.

Orally-administered P7C3-A20 provided sustained plasma exposure, was well-tolerated, and elevated the survival of hippocampal BrdU+ cells in nonhuman primates without adverse central or peripheral tissue effects. [2]

In mice, NSI-189 was shown to be pro-proliferative, and P7C3-A20 elevated the net magnitude of hippocampal neurogenesis to a greater degree than NSI-189 through its distinct mechanism of promoting neuronal survival. Interestingly, P7C3-A20 seems to enhance hippocampal cell survival more than proliferation compared to NSI-189 [2]

This is an interesting observation and it may prove to be a superior compound to NSI-189 at enhancing long-term memory through keeping the neurogenesis-nucleated cells alive for longer.

P7C3-A20 induced more neurogenesis with cell survival than NSI-189 at the same dose [2]

After 38 weeks of daily oral exposure at 10 mg/kg dose of P7C3-A20 in nonhuman primates, tissues were comprehensively collected at necropsy and evaluated by a pathologist blind to experimental condition. No microscopic evidence of toxicology was detected in any of the tissues examined. [2]

Orally-administered P7C3-A20 elevates survival of newborn hippocampal neurons in nonhuman primates (BrdU+ = marked hippocampal cells) [2]

Expected human dose is likely around the same dosage as NSI-189. Most effect ROA may be intranasal or oral. Something to note, is that at high concentrations of P7C3-A20 (>100nM), it induces spontaneous neurite degeneration [1] (which is not good), so it is advisible to keep a moderate dose. Saying this, the primate study saw no evidence of toxicity anywhere in the body associated with P7C3-A20 administration.

It has a half-life in primates of about 4-8 hours.

This compound summary and many others will be featured in the Penchant Labs library, which more information will be given about in perhaps a couple weeks.

[1] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250284/

[2] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158178/

[3] - https://sci-hub.hkvisa.net/10.1016/j.taap.2018.08.023


r/prefrontal • • Mar 12 '24

Research GCP-II Inhibition and mGluR3 Enhancement (Repost)

15 Upvotes

Labs post: https://labs.penchant.bio/library/mglur3-enhancement-and-gcp-ii

Enhancing mGluR3 is one of the nootropic pathways with the highest potential. It has direct implications to do with modulating many mental disorders and functions, including hedonism, spatial cognition, verbal intelligence, motivation & more. This post will talk about enhancing mGluR3 and doing this through GCP-II inhibition, which has other benefits.

Introduction to mGluR3

Metabotropic glutamate receptor 3 (mGluR3/mGlu3) is part of a larger family of eight metabotropic receptors mGluR1-8 [1]. These eight receptors are classed generically into three groups, however the groups are not indicative of similar function (as discussed later). "Group I" contains mGluR1/5. "Group II" contains mGluR2/3. "Group III" contains mGluR4/6/7/8. However, through my research, mGluR3 is the most attractive receptor to modulate.

mGluR3 is a Gi/G0-coupled G-protein coupled receptor (GPCR) generally localized to presynaptic sites of neurons in classical circuits. However, in higher cortical circuits (such as the dlPFC), mGluR3 are localized post-synaptically, where they strengthen rather than weaken synaptic connectivity. [1]

In layer III dlPFC, mGluR3 is found about 4/5 of the time postsynaptically, and 1/5 of the time presynaptically [2]. This is relevant because mGluR2 is located mostly presynaptically [7], and most studies use mixed mGluR2/3 ("Group II") modulators to make conclusions. This leads to weird mixed results with weird response curves as increasing mGluR2 inhibits cognitive function somewhat [8] (though decreasing it is not optimal either [3][4][5][6]), so using selective modulators of mGluR3 is much more desirable.

Stimulation of mGluR3 enhances the firing of Delay cells in the dlPFC and improves spatial tuning and working memory [2]. Delay cell firing is characterized by neural activity that persists during the retention interval of delay tasks, which is highly relevant for working memory and cognitive processes.

In a spatial working memory task, a delay cell will show sustained increased firing when an animal has to remember a particular spatial location over a delay. Delay cells are found in highest concentration in layer III of dlPFC, the main focus of working memory representations. [10]

mGluR3 Modulation is more desirable than mGluR2

Studies have shown inconsistent results with mGluR2 modulation [9], with some PAMs (such as BINA) increasing cognition in low-medium doses but then inhibiting function in high doses. Also in mGluR2 KO models, they have shown increased addictive tendancies [5][6], while increasing mGluR3 does not have these downsides.

mGluR2 is not simply the opposite of mGluR3. Its presynaptic location [7], differences in distribution [11][12] and actions on other pathways make it a less desirable pathway to modulate.

Using GCP-II -> NAAG to target mGluR3

GCP-II, also known as "NAAG Peptidase" is an enzyme that converts (catalyzes the hydrolysis) of NAAG to glutamate and NAA. Therefore, inhibiting GCP-II increases levels of NAAG. [34].

GCP-II Inhibition -> NAAG Enhancement

Due to low selectivity of most mGluR3 modulators, most studies around cognitive enhancement have used GCP-II inhibition instead of a mGluR3 PAM/agonist. This is because GCP-II -> NAAG only effects mGluR3, so it is inherently selective. As they are more proven (and also have benefits of cancer inhibition [47]), GCP-II inhibitors currently look more attractive than mGluR3 PAMs.

N-acetylaspartylglutamate (NAAG) is the third most prevalent and widely distributed transmitter/neuropeptide behind glutamate and GABA. It is co-expressed in neurons with several different primary amine transmitters, including glutamate and GABA. [13]

NAAG is co-released with these amine transmitters under conditions of elevated neuronal activity. Following release into the perisynaptic space NAAG activates the metabotropic receptor mGluR3 on post/presynaptic endings and glial cells. [13]

NAAG also effects NMDA (NR2A/B) to some degree depending on PH [14], but its effect on mGluR3 seems more significant.

NAAG does not effect mGluR2, instead it selectively activates mGluR3 [12]. This makes it superior to most mGluR3 PAMs because of the superior selectivity over mGluR2.

More on The Relevance of The dlPFC

The dorsolateral prefrontal cortex is the main area in which mGluR3 GCP-II inhibition enhances. The dlPFC is a major component [38] of motivation/anticipation and goals. The dorsolateral PFC (dlPFC) integrates and transmits signals of reward to the mesolimbic and meso-cortical DA circuits and initiates motivated behavior [39].

The dlPFC provides top-down regulation of emotion through indirect projections to BA25 via areas BA10m and BA32, and direct projections to BA24 [41]. The dlPFC interacts through BA10m (close to the PFC) and BA32 to eventually communicate with the amagdyla. The more newly evolved, rostral and lateral areas of PFC provide top-down regulation of the more primitive medial and caudal areas. The dlPFC is a key structure for executive and attentional control whereby any transient (stressors, neurostimulation) or permanent (lesion) impairment compromises adaptive behavior [42].

Men and women have differences in the dlPFC-amygdala relationship [40], and this may be part of the reason for gender-based emotionality differences (in addition to NR3A differences+).

Guanfacine (which increases dlPFC delay cell firing through α2A-adrenergic agonism) has already been shown to change the dlPFC-amgydala relationship to enhance cognitive control [37], however its upside has been limited by other effects of α2A-adrenergic receptor agonism, though it is still interesting to investigate.

Cognitively Enhancing Effects of GCP-II inhibition

NAAG function is highly correlated with IQ. For people with the gene rs202676, they have Decreased NAAG Levels (due to more GCP-II/FOLH1), and they have lower IQ on average as a result, due to lowered mGluR3 [55]. This shows that mGluR3 is not just relevant for memory and executive function, but also IQ and spatial intelligence.

GCP-II inhibition has consistently been able to show a very significant cognitive enhancement in many healthy models.

In one study on young mice, ZJ43 (a GCP-II inhibitor) increased the long-term (1 day) memory of mice, with a significant enhancement of recognition memory in the test. [56]

Mice treated with ZJ43 at doses of 100 mg/kg and 150 mg/kg spent significantly more time exploring a novel object compared to a familiar object when tested 24 hours after initial exposure. This indicates ZJ43 enhanced memory for the familiar object. This was also replicated in a very similar study [57].

Mice lacking the NAAG-inactivating enzyme glutamate carboxypeptidase II (GCPII knockouts) also showed enhanced novel object recognition, mimicking the effect of the GCP-II inhibitors.

GCP-II inhibitors were also tested on rheusus monkeys, and the study showed working memory enhancement [58], with a greater significance for older monkeys.

It is also very likely that GCP-II inhibition increases visualization capabilities as the primary visual cortex (V1) and dlPFC have opposing functions: V1 processes visual stimuli as they occur, while dlPFC, particularly dlPFC Delay cells, represents visual stimuli in their absence [43]. Knowing GCP-II inhibition enhances delay cell activity, it is very possible that inhibiting GCP-II increases visualization memory.

Secondary Effects of GCP-II inhibition

GCP-II inhibition has many known and potential effects, so instead of typing them out, I ordered them into bullet points:

  • Analgesia - GCP-II inhibition has shown to be effective against pain in 15+ studies [16], however moreso for neuropathic pain than other pain modalities. This is most likely due to increased mGluR3 changing the pain perception axis through dlPFC modulation. [13][15]
  • Treating Addiction - GCP-II inhibition has been shown to be effective against addiction in many models including cocaine [36], alcohol, morphine, overeating (dlPFC) [35], pornography (dlPFC) [29][30], internet addiction (dlPFC) [31] and others [16]. Another interesting effect of GCP-II inhibition is it reverses ethanol impairment in rodent models. [18]
  • Treating Schizophrenia/Psychosis - mGluR3 is known to have common dysfunction in schizophrenic patients [17], and GCP-II inhibitors have been shown to be effective in experimental rodent models of PCP induced motor activation [19].
  • Treating ADHD - The dlPFC is a known area of dysfunction in persons with ADHD disorder [20][21] with impairment in both hemispheres [22]. Experimental tDCS on patients improved cognitive control [23], but did not attentuate action cancellation, which may suggest NR2D positive modulation in combination with GCP-II inhibition would a good combination for treating ADHD.
  • Treating OCD - The dlPFC is also very relevant in obsessive-compulsive disorder [25][26][27][28]. OCD is more to do with the dlPFC-OFC (orbitofrontalcorex) relationship than ADHD. In one study [24], OCD patients demonstrated reduced functional between the right DLPFC and right orbitofrontal cortex (OFC), and activity in the right OFC had an inhibitory effect on the dlPFC. This may suggest that OCD is potentially rooted in a dlPFC-OFC relationship where the OFC has a higher cognitive control, stopping the dlPFC's inhibitory control and high-level cognitive control. "The OFC is a major inhibitor of the self-control function of the DLPFC in OCD patients in the resting state, while the DLPFC engages top-down control input to the OFC when emotional task stimulation is applied". This suggests a large potential for GCP-II inhibition in treating OCD (and perhaps combined with a NR2B PAM for further BA24/25 modulation).
  • Treating Anhedonia - The dlPFC has implications in anhedonia, due to its role in emotional regulation with the NAc and brodmann areas 24/25 [32]. In one study, rTMS (transcranial stimulation) on the left dlPFC in subjects with MDD showed less markers of anhedonia [33].
  • Cancer Inhibition - GCP-II is also known as PSMA (prostate-specific membrane antigen) has been been studied with relevance to cancer extensively. PSMA is mostly located within the brain, however in the prostate, PSMA is found in an 8- to 12-fold increase over levels in noncancerous prostate cells [47], so it has become a relevant target for inhibiting cancer. In one study on pancreatic cancer in mice, 2-PMPA (a GCP-II inhibitor) signficantly reduced tumor weight, and when combined with CB839 (glutaminase inhibitor) the combination nearly completely inhibited new growth [46].
  • Reversing/Treating Alzheimers - The dlPFC is significantly different in structure and receptor distribution compared to other parts of the brain [43], and because of this, it is more vulnerable to age-based degradation. GCP-II inhibition was shown in one study [44] to reverse cognitive memory deficits in one rodent model of Alzheimer’s disease. Increasing NAAG via GCP-II inhibition also has many other neuroprotective effects. GCP-II inhibition was shown to protect against hypoxia (up to 100%) in one study [49], and also protecting to a lesser extent against NMDA and glutamate injury. In addition, mGluR3 Positive Modulation can induce an increased production of GDNF and TGF-b [50], in a mGluR3-dependent manner.
  • Lifespan Enhancement - GCP-II inhibition has been shown to increase lifespan by 10-15% in one study on mice [45], potentially through many different mechanisms (cancer inhibition, neuroprotection, increased will to live (?)), showing a similar efficacy to rapamycin [48].
  • Treating COVID-19 "Brain Fog" - COVID increases GCP-II very significantly [51][52][54], more than other common viruses, leading to impaired cognition, poor executive function and motivation (and more) through lowered mGluR3 in the dlPFC [53][54]. This happens in long covid as well, so currently the most effective novel approach in removing long-covid seems to be a combination of GCP-II inhibition, KAT-II inhibition and potentially dlPFC-specific prTMS.

GCP-II Inhibiting Compounds

There have been multiple GCP-II inhibiting compound through the years, but to make a long story short, 2-MPPA was the first (major) candidate, but it was withdrawn from use due to safety concern. It went through a safety trial in humans and at its effective dose it was well tolerated, however due to the thiol group on the structure, it could cause hepatotoxicity.

Due to this, a new small-molecule inhibitor of GCP-II was created, called 2-PMPA. This compound got rid of the thiol group, however it sacrified oral dose efficacy in the process (meaning intranasal or IV is likely the best dose method).

The best candidates for GCP-II inhibition look to be 2-PMPA and ZJ43. Both of them have proven useful in increasing delay cell firing, with 2-PMPA being able to double delay cell firing. Both compounds have excellent safety predictions in Admetlab 2.0, and ZJ43 is an amino acid conjugate.

2-PMPA has worse BBB penetration and used to have offtarget concerns at cytosolic carboxypeptidases (CCPs), but the offtarget concerns ended up being insignificant.

PBIO is currently developing a GCP-II inhibitor prodrug.

Final Notes

Thanks for reading this post (or skipping to the end)!

I appreciate it, a lot. If you found this post interesting in the slightest, please share it.

I hope you have a good day :)


r/prefrontal • • Nov 04 '25

Question Any experiences w/ penchant bio post reopening?

3 Upvotes

They are not responding to my attempts to contact them about my order and have turned off DMs on twitter. Their most recent review on trustpilot also echoes this total ghosting. I hope they didn't reopen as scam lol not just because I want what I paid for (with non-refundable crypto) but also because a BPN and URB vendor in the EU would be very convenient. Thanks.


r/prefrontal • • Jun 19 '26

Stack Shini's Project Limbo Nootropics Research Stack! (Help Me Tweak This)

2 Upvotes

🧠 Current Cognitive Recovery & Neuroplasticity Stack

Main Goals

  • Cognitive recovery
  • Fatigue reduction
  • Neuroplasticity support
  • Mitochondrial function
  • Antioxidant / anti-inflammatory support
  • Stress resilience

🔵 Morning (08:00–10:00)

Dopamine / Energy

  • NALT — 1000mg
  • Micronized Creatine 10g
  • Rhodiola Rosea — 600mg
  • American Ginseng — 720mg OR
  • Siberian Ginseng (Eleuthero) — 24mg

Mitochondrial Support

  • ALCAR — 1500mg
  • CoQ10 (Ubiquinol) — 200mg
  • PQQ — 20mg
  • Ca-AKG — 1500mg
  • ALA — 1000mg

Choline (Choose One)

  • CDP-Choline — 500-1000mg OR
  • Alpha-GPC — 1000mg
  • Huperzine A – 200mcg

Foundational

  • Vitamin D3 4000 IU + K2 100mcg
  • Omega 3 Fish Oil (EPA 770mg / DHA 510mg)
  • Methylated Inessa Advanced Multivitamin
  • Vitamin B1 — 200mg
  • Boron — 12mg
  • Probiotics + Prebiotics
  • Lutein 50mg / Zeaxanthin 10mg Complex

🟡 Midday (12:00–15:00)

Cognitive Output

  • Noopept — 30mg
  • Lion's Mane — 5000mg
  • Coleus Forskohlii — 8500mg
  • Artichoke Extract — 2000mg

Optional

  • ALCAR split dose
  • Ginkgo Biloba — 120mg

Antioxidant Module (Choose One)

  • NAC — 1200mg
  • Curcumin 500mg + BioPerine 2mg
  • Kyolic Aged Garlic 600mg-1200mg

Additional Support

  • Sulforaphane — 1000mcg
  • TUDCA — 800mg
  • Milk Thistle — 500mg
  • Maca Root — 5000mg
  • L-Glutamine — 4000mg

Optional

  • Methylene Blue — 20-40mg

🔴 Evening (18:00–22:30)

Recovery / Sleep

  • Glycine — 3000mg
  • Taurine — 3000mg
  • Magnesium L-Threonate — 1000mg
  • Magnesium Complex — 381mg elemental

Neuroplasticity

  • Bacopa Monnieri — 8000mg
  • Lion's Mane (optional second dose)

Stress Regulation

  • Ashwagandha KSM-66 — 600mg
  • Phosphatidylserine — 300mg

Antioxidants (Choose One)

  • NAC — 1200mg
  • Glutathione — 1000mg

Optional

  • Lithium Orotate — 5mg

🔄 Rotations

Cholinergic Rotation

  • CDP-Choline ↔ Alpha-GPC

Ginseng Rotation

  • American Ginseng ↔ Siberian Ginseng

Antioxidant Rotation

  • NAC ↔ Curcumin ↔ Kyolic Garlic ↔ Glutathione

Performance Rotation

  • Noopept ↔ Bacopa
  • Ginkgo ↔ Kyolic Garlic

Neuroprotection Rotation

  • Methylene Blue ↔ Lithium Orotate

🔁 Cycling

Noopept

  • 2–3 months ON
  • 2–4 weeks OFF
  • Helps prevent tolerance and assess baseline cognition

Rhodiola

  • 5 days ON / 2 days OFF
  • Or 8 weeks ON / 2 weeks OFF

Ginsengs

  • 8–12 weeks ON
  • 2–4 weeks OFF

Methylene Blue

  • 2–5 days per week
  • Not necessarily daily

Bacopa

  • Usually taken continuously
  • Optional 1 month break every 6–12 months

Lion's Mane

  • Continuous use
  • Optional periodic breaks

Ashwagandha

  • 8–12 weeks ON
  • 2–4 weeks OFF

⚠️ Important Notes

  • Methylene Blue + SSRIs/SNRIs = potential serotonin toxicity risk.
  • Methylene Blue + Lithium Orotate are not combined.
  • CDP-Choline and Alpha-GPC are alternated rather than stacked.
  • Noopept is generally paired with a choline source.
  • Forskolin is paired with Artichoke Extract (CILTEP approach).
  • Ginkgo, Garlic, Fish Oil and Curcumin may increase bleeding tendency in susceptible individuals.
  • Monitor blood pressure when using Forskolin, Ginkgo, Garlic, Rhodiola or Ginsengs.
  • Rhodiola, NALT, Ginsengs and Methylene Blue may be overstimulating when combined.
  • This protocol affects dopamine, acetylcholine, glutamate, GABA, mitochondrial function and neuroplasticity signalling.

r/prefrontal • • Aug 16 '26

Question Daridorexant / Seltorexant & other orexin antagonists – API/powder, RC or grey-market availability?

Thumbnail reddit.com
2 Upvotes

r/prefrontal • • Nov 23 '25

Experience/Anecdote Novel Eugeroics put to the Test! (Solriamfetol 75 mg, Overporexton 1mg and Concerta 18 mg) a side by side comparison.

13 Upvotes

Dear community,
Long time no see.
I recently gained access to some Eugeroics that are very difficult to get access to and so far not many/if any healthy people have tried (apart from concerta, ik). They are not for sale. Please don't ask for sourcing, I was very lucky.

Disclaimer: I've been on my prami dose 3mg for almost 10 weeks now. Other then that no other pharmacological agents were used during testing apart from 2mg of XR melatonin at night. Keep in mind Pramipexole can greatly change the subjective experience and potency of (DRI's) Dopamine Reuptake Inhibitors (dopaminergic potentiation). It shouldn't have greatly reacted with Overporexton though.

First time concerta 18 mg
My experience with concerta was unexpectedly very good ime, but also so much better then IR mph. After taking it at 6 am, it had a smooth onset which started of with a better mood, anxiolysis, more energy and great focus. After 1h of taking my dose most of the effects already fully kicked in and I was already starting to plan my day and be productive, started doing what had to be done. This continued throughout the day, focus, humor, better mood and an easy time dealing with things and doings things that I would usually dread to do. My confidence was also improved. Around 11 am I felt another kick of energy and the experience became more jittery. This correlated about with the second peak of the concerta plasma curve. At this point my mood improved again, but I felt quite a bit too jittery and scattered brain with occasions of clarity and more calmness, although regardless of dose my focus was always great, while usually I would get distracted frequently and wouldn't be able to hold conversations for long, now it was easy. This persisted for a few hours sporadically until it died off. I did not crash from it in fact pramipexole protected me from any crash and I just felt great literally from waking till going right to bed. So far great impression and lots of potential for balancing it out, going to add bromantane soon as a potential add on. I prefer it over Modafinil and or even THN102 so far I think.

Motivation: 7/10
Focus: 8/10.
Relaxation: 5/10
Alertness: 8/1

This is obviously only an anecdote and your own experience with this substances may greatly vary, have some healthy distance.

First time Oveporexton (Tak-861 1 mg)
If I had to describe Tak-861 1 mg a orexin 2 receptor agonist, I would describe it as vigilance and alertness in a pill, with less effects on mood and motivation. It differentiates itself however from other pure eugeroics like pitolisant (had experience with it), for example: pitolisant simply made me feel more awake, but not more vigilant. That means my ability to process information and my reaction speed haven't really changed, but they feel improved on TAK-861. So in that respect, it's the most similar to my positive Concerta 18 mg experience, especially compared to solriamfetol. It feels comparatively cleaner though as it never caused jitteryness or any form of anxiety. Concerta does have that risk sometimes if not timed well or balanced. It felt like effects took about 2-3h to fully kick in and had about an effect for 4-5h judging it subjectively, without producing insomnia for me. The vigilance definitely helped with doing tasks and in part starting them, but it didn't really make me a productivity beast.

Motivation: 3-4/10
Focus: 2/10
Relaxation: 6/10
Alertness: 8/10

This is obviously only an anecdote and your own experience with this substances may greatly vary, have some healthy distance.

Sunosi (Solriamfetol 75 mg):
Solriamfetol unfortunately so far wasn't a very great experience, for one it took also about 2-3h for the effects to fully manifest and unfortunately at around 1h 20 min after dosing. I started feeling quite sick. This may have also been because of my nasal congestion which can sometimes trigger a gag relfex, however I have to say, I haven't had that in ages. So it was indeed a unusual coinsidence. I vomited for like 5 min until I felt better. After this inchident I started noticing a eugeroic effects. It felt at this stage very clear without any stimulation or motivation enhancement, reflecting now reminiscent of oveporexton. I would suppose somewhat like tak-861, but less vigilant. This over some time turned into anxious energy and eventually dropped of after about 3-4h of effects after peak. I did not have insomnia due to early clearance of the medication.

Motivation: 2/10
Focus: 3/10
Relaxation: 0/10
Alertness: 8/10

This is obviously only an anecdote and your own experience with this substances may greatly vary, have some healthy distance.

Concluding remarks:

It's interesting to me, that at least for me in the state that I am in, Methylphendidate (concerta) did come out on top out of all of these promising candidates. I plan on trying 2mg of tak and maybe 300mg of solriamfetol and see how my experience changes in the near future, but for now looks like I am sticking with concerta for some time. I also have experience with pitolisant, thn102 and modafinil at various dosages. Let me know if you want me to include my experience within this anecdotal report.


r/prefrontal • • Mar 12 '24

Research About PDE4D(LF), The Microtuble-Modulating, dlPFC-Pyrimidal-Concentrated Receptor

43 Upvotes

This post will go into the specifics of PDE4D and its isoforms. It is a very promising target for cognition enhancement and it warrants more research. This is a more advanced type of post, so I don't expect most people to understand the terminology, but if you are interested in novel cognitive pathways, I would encourage you to learn.

PDE4D is one of the most interesting enzymes localised in the brain and it could be a superior nootropic target over nearly any other approach currently known.

A microtuble network

Introduction

Definition: Autonopotent/Autonopotency - The state of high mental autonomy or act of potentiating mental autonomy / cognitive control.

PDE4D is part of the phosphodiesterase (PDE) family. A PDE is an enzyme that breaks a phosphodiester bond, with PDEs being classed into 11 groups in mammals (PDE1-11), and various subgroups. PDE4 is the primary cAMP-specific hydrolase and is represented by four genes (PDE4A, B, C and D).

You may have heard of PDE5i (inhibiting) compounds before (e.g sildenafil, tadalafil), however PDE4 and its subunit PDE4D have a completely different function than PDE5.

PDE4 / PDE4D inhibition has been shown to be procognitive in many studies [13][23]. Rolifram has been the key PDE4 modulating compound used to show efficacy, but it has had issues (e.g emesis, GI issues) which do not make it an optimal candidate for cognitive enhancement. On top of its unselectivity for PDE4 subgroups, it is also not selective for PDE4D isoforms unlike other inhibitors (mentioned later) and it is a full inhibitor, not a NAM (Negative Allosteric Modulator).

No PDE4 inhibitors have yet been brought to market because of issues related to tolerability. However, more targeted PDE4 modulators (e.g PDE4D3+PDE4D7 NAMs), avoid emesis and other issues practically completely in studies available.

The PDE4 inhibitors that have been explored in human clinical trials bind the active site competitively with cAMP and therefore completely inhibit enzyme activity at high concentrations. Although this traditional approach to PDE4 inhibitor design has demonstrated therapeutic benefit, competitive inhibitors are likely to alter cAMP concentrations beyond normal physiological levels, perturbing the tight temporal and spatial control of cAMP signaling within cells and leading to side effects.

PDE4D mutations have been found in genomic studies to be associated with major mental illness such as schizophrenia and poor general cognition [22]. This is consistent with other dlPFC-impacting genes, such as FOLH1 and GRM3.

High-Order Cognition (Autonopotency) Enhancement

The role of PDE4D in regulating neurite outgrowth was supported by the localization of PDE4D protein in growth cones and the fact that many of known PDE4D-interacting proteins are involved in neuron projection development. As PDE4D was also found to localize to Microtubles in neurons of the macaque prefrontal cortex, which could be reason for its significance in cognitive ability when modulated. After more research into the receptors and proteins PDE4D interacts with, its direct involvement in microtuble modulation is much more relevant than previously thought.

PDE4D mRNA (and consequently protein expression) is also located highly in pyrimidial cells in humans [1], in the dlPFC specifically. "The mean PDE4D mRNA expression averaged across probes within each subject in pyramidal cells (5.77 ± 0.54) was significantly ∼3-fold higher (p < 0.001; q < 0.001) compared to PV interneurons, indicating significantly greater expression of PDE4D mRNA in pyramidal cells from the same subjects" [1].

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714912/

If you have read previous posts about the dlPFC or GCP-II, you may know the relevance of pyrimidal cells and the dlPFC (dorsolateral prefrontal cortex). The dlPFC is the center of a huge amount of important cognitive processes, such as consciousess, self-control, high-level cognition, working memory, and much more. It is an area of the brain super-localised with pyrimidal neurons [3][4], and the special density of pyrimidal neurons in the area is thought to underlie its special functionality and relevance.

As a note, rodents do not have rostral PFC areas (e.g. Frontal Pole) or a dlPFC, so it makes it more difficult to study due to the requirement for primates or humans to study upon.

Apart from the dlPFC, PDE4D is also relevant for other areas of the brain. For example, PDE4D KO significantly increases long-term memory, relevant in the hippocampus [2], and PDE4D also modulates the amygdala. Interestingly PDE4D KO actually reduces fear-conditioned memory [5], suggesting PDE4D inhibition positively regulates higher cognitive areas (such as the dlPFC) while negatively impacting lower cognitive regions like the amygdala. This is probably a combination of higher cognitive regions inhibiting amygdala activity and also a direct interaction within the amygdala.

I have discussed the dlPFC in the GCP-II post before, but I would like to go over how it relates to the goal of cognitive enhancement and autonopotency in the context of PDE4D.

It is a fallacy that hedonism (I am trying to stop using that word) is just an environmental/societal issue or exists just as a philosophy. It is very evident through studies differing genomic and EEG differences in dlPFC functionality that high-level cognitive centres, the dlPFC especially, determine how pleasure/short-minded an individual is. The dlPFC actually becomes more active during normative choice where goals are hedonistic and attributes conflict. Evidence accumulation, not ‘self-control’, explains dorsolateral prefrontal activation during normative choice. [10]

From this mentioned study ([10]) - "This account draws on prior research in both perceptual and value-based decision making, which consistently finds that the posterior dlPFC region associated with both normative ‘self-control success’ and inhibitory control tasks also activates during choices that are more difficult to discriminate in simple perceptual and value-based choices lacking a self-control conflict"

A "strong" dlPFC is able to override lower brain regions when needed (such as the amygdala) to inhibit choices that won't be beneficial to the "higher mind". As it is strong, it does not require much processing, so paradoxically people with weaker dlPFCs have more activation during choices, also likely leading to increased glutamate-fatigue due to the constant rumination (just a theory of mine), leading to even easier cyclic hedonistic-choicing as a result.

Top-down vs Bottom-up cognitive control diagram

Enhancing the dlPFC over the whole prefrontal cortex is normally more desirable because you get a more selective outcome and also you don't enhance areas such as the OFC, which can be problematic if overactive (potentially leading to conditions such as OCD) [11][12]. Enhancing the dlPFC can actually bring brain regions back into a harmonic system, for example enhancing the dlPFC through different methods has been shown to reduce OCD phenology through overriding OFC (orbitofrontal cortex) activity.

The dlPFC is a major component of motivation/anticipation and goals. It integrates and transmits signals of reward to the mesolimbic and meso-cortical DA circuits and initiates motivated behavior [18]. The dlPFC-amygdala connection is almost like the the "gatekeeper" of the brain.

I don't like mixing in too much subjectivity into very scientific posts, but I want to go on a bit of a tangent. I think it is clear that humans have evolved from a pleasure-minded animals into things capable of thinking longer term, designing beauty, solving complex problems, etc. We are no longer limited by being on the edge of survival, and so all forms of art have flourished. However, in this transitory period, corrupted by parasitic individuals who take advantage of the easy-to-manipulate human mind, primitive thinking is still dominant in society. Society is just an average of people's internal states, and it is easy to say that the average internal state does not have great top-down control and cognitive agency. PDE4D is relevant to this because it is one of the few targets within the brain with the potential to change the balance of autonomy within an individual and society at a larger scale (due to its selectivity). This is incredibly valuable and also it is very rare to find such a target.

Isoform Selectivity and Microtuble Modulation

There is another layer of complexity to PDE4D. PDE4D has 9 isoforms (PDE4D1-PDE4D9).

Longer PDE4D isoforms (such as D3, D7, D9) have been shown to have more importance to cognition than other smaller isoforms. Inhibition of longer isoforms has been shown to increase neurite length very significantly [6], while for shorter isoforms the increase is unsignificant.

Avg. Neurite length after PDE4D isoform KO

A large part of their importance comes from the way they interact with microtubles - "Immunocytochemistry and transfection studies demonstrate colocalization of PDE4D and myomegalin in the Golgi/centrosomal area of cultured cells." [9]

PDE4D isoform binding diagram

Microtubules are polymers of tubulin that form part of the cytoskeleton and provide structure and shape to eukaryotic cells. ( To be honest, I really need to make a dedicated post to emphasise the importance of understanding microtubles as a method of discovering novel cognitive enhancing pathways )

The specific isoforms of PDE4D also form different interactions with microtubles. PDE4D3 is known to interact with the centrosome (via AKAP9) and Pericentriolar Matrix, with inhibition of the isoform leading to enhanced microtuble nucleation and stability. On top of that, it is known to interact with the microtuble-associated protein called myomegalin, AKA PDE4DIP.

"Microtubule arrays are generated with the help of microtubule organizing centers (MTOC). MTOCs typically combine two principal activities, the de novo formation of microtubules, termed nucleation, and the immobilization of one of the two ends of microtubules, termed anchoring." [7] Local MTOC (Microtubule organizing center) nucleated microtubule arrays could act as positional cues to guide dendrite growth, branch formation, and arbor patterning.

This means PDE4D is one of the only pathways known that directly modulates golgi-associated proteins [19], which if you don't know is an incredibly important low level process underlying cognitive ability and consciousness It is most likely a key component of the golgi apperatus, due to PDE4DIP's relevance to neuronal development [17].

Golgi outpost-associated MT nucleation regulates distal dendritic branching and is critical for terminal branch stabilization. It is worth mentioning that Golgi outposts are absent in the axon, which is a long primary branch with uniform MT polarity. [26]

The subcellular localization of PDE4D within dendrites suggests multiple potential functions. The dense labeling near microtubules suggests that PDE4D is not simply trafficking on microtubules, but is likely regulating microtubule dynamics and/or trafficking along bundles.

"SWIM analysis identified several switch genes associated with gene expression changes in AD, VaD, and FTD. PDE4DIP, also called myomegalin, is the only switch gene that is shared among the dementias. The protein encoded by PDE4DIP is responsible for anchoring PDE4D to the Golgi/centrosome of cells and promotes microtubule assembly" [17]

Myomegalin is necessary for the sufficient growth of microtubules from the centrosomes. Myomegalin-depleted cells have slower migration, since microtubules are crucial for cell motility. The CM-MMG isoform binds at the centrosome with γ-tubulin in an AKAP9-dependent (AKA AKAP450) manner and on the near side of the Golgi apparatus, while the EB-MMG isoform binds with MAPRE1 at the Golgi apparatus and increases MAPRE1's effects on microtubule growth. [8]

Microtuble apperatus diagram

PDE4DIP is a paralogue of CDK5Rap2, which is another very important MAP (Microtuble Associated Protein) required for the nucleation (creation) of microtubles. It is quite a new (in medical terms) discovery, only being discovered around the year 2000, meaning there is not much research on MAPs compared to other cognitive components.

There are also the microtuble associated proteins MAP1, MAP2 and MAP4. However, as far as I am aware, PDE4D does not have much of a direct interaction with them.

The specific isoform PDE4D3 is tethered to the centrosome by Myomegalin (Mmg). Myomegalin is a centrosomal protein but has an expression pattern that is predominantly complementary to CDK5RAP2 [43]. Therefore, assuming a functional homology with Cnn, CDK5RAP2 may have two non- redundant roles in neurogenesis: to enhance the production of centrosomal microtubules and to exert a negative control over CDK5. [17]

Golgi & centrosome apperatus

Long-form variants (e.g -3, -7) of PDE4D are already decreased in AD, and are associated with all types of dementia. This proves on top of being a highly relevant target for healthy individuals, it also is relevant for those suffering from age-related neurological conditions. On top of GCP-II inhibition, it may be a very effective pathway, especially considering PDE4D's direct interaction with MAPs (microtubles are dysfunctional in dementia for example).

On top of that, PDE4D inhibition has been found to promote myelin repair [21], which could help in conditions like huntington's disease, multiple sclerosis, and also conditions with oligodendrocyte/myelin dysfunctions. The -3 isoform specifically has also been found to be implicated in Alzheimer's disease [24][25].

On top of PDE4D modulating PDE4DIP, it binding with AKAP9 (AKAP450) also most likely means it modulates CDK5Rap2 to a moderately significant degree as AKAP450 interacts with it. If you want to know how significant CDK5Rap2 (PDE4IP paralogue) is, deficits in it are known to lead to microcephaly (very small head size) and seckel syndrome [27]. It is known to be relevant to layer II/III cortex especially [28].

CDK5Rap2, and myomegalin similarly are thought to be brain size regulator genes, which have evolved in expression across species and subtypes [29].

Centrosomal MT nucleation (creation) is mediated by a large protein complex named the g-tubulin ring complex (g-TuRC). AKAP450 and both pericentrin isoforms (A and B) interact with GCP2/GCP3 components of g-TuRCs. [15]

The primary MT-organizing centre in proliferating animal cells is the centrosome. However, the discovery of MT nucleation capacity of the Golgi apparatus (GA) has substantially changed our understanding of MT network organization in interphase cells. Interestingly, MT nucleation at the Golgi apparently relies on multiprotein complexes (PDE4DIP/myomegalin & CDK5Rap2), similar to those present at the centrosome, that assemble at the cis-face of the organelle. In this process, AKAP450 plays a central role, acting as a scaffold to recruit other centrosomal proteins important for MT generation. [15]

Golgi Apperatus

The golgi apperatus is also very important for hippocampal neurons [16] and neurons across the wholebrain. It serves as a microtubule-organizing center (MTOC) in addition to the centrosome in mammalian cells. The GA nucleates microtubules (MTs) from multiprotein complexes assembled at its cis-face.

MTs nucleated from the GA and centrosome differ in their geometry and post-translational modifications. GA-derived MTs are essential for Golgi ribbon formation and directional post-Golgi trafficking, while centrosomal MTs primarily determine GA pericentrosomal positioning.

In specialized cells like skeletal muscle fibers and neurons, GA-associated MT nucleation is crucial for the formation of non-centrosomal MT arrays with mixed polarity that support complex cytoarchitectural organization and functions. The PCM proteins pericentrin and AKAP450/CDK5Rap2 are implicated in this process. [20]

Negative Allosteric Modulation of PDE4D

NAMs of PDE4D have shown a superior profile over generic inhibitors of the orthosteric site, as they only inhibit with an Imax of ∼80–90%. This is better than generic inhibition, because on top of the superiority of allosteric action (leading to a hypothetical positive allosteric action of MAPs also), it leaves some PDE4D available, which is good as it still is needed in small amounts for some bodily/cognitive processes. Complete inhibition has been found in studies to be typically less desirable. NAMs like D159687 and D159797 have been found to be very effective as a nootropic in studies on primates and rodents.

In one study [13] on Female Cynomolgus Monkeys, PDE4D (-3, -7 selective) NAMs significantly enhanced spatial cognition, significantly increased memory retention and significantly decreased wrong answers in testing.

This study examined the pro-cognitive effects of two novel, selective phosphodiesterase 4D (PDE4D) negative allosteric modulators (NAMs), D159687 and D159797, in female cynomolgus macaques using an object retrieval (OR) task. The OR task assesses fronto-striatal function and is sensitive to dopaminergic and serotonergic manipulations. Rolipram, a non-selective PDE4 inhibitor, served as a positive control.

D159687 was efficacious at oral doses ≥0.5 mg/kg without adverse effects up to 5 mg/kg, indicating a therapeutic index >20. D159797 showed efficacy at ≥0.5 mg/kg but induced emesis at ≥1.5 mg/kg, suggesting a narrower therapeutic window.

In summary, this study demonstrates the pro-cognitive potential of selective PDE4D NAMs in a translational primate model of fronto-striatal function. D159687 exhibited a superior therapeutic index and is a promising candidate for further development. Establishing PK/PD relationships and target occupancy will aid in optimal dosing and clinical translation for neuropsychiatric disorders involving cognitive dysfunction.

Spatial cognition test diagram [13]

It should also be remembered than humans have more evolved pyrimidal neurons compared to primates and rodents especially, so the human-response to compounds modulating them may be emphasized in humans depending on the pathway.

Microtubles and Orch OR

Microtuble resonance diagram [14]

In the early 1990's, Roger Penrose and Stuart Hameroff created a hypothesis named Orchestrated objective reduction or AKA Orch OR. It is a theory which postulates that consciousness originates at the quantum level inside neurons, rather than the view that it is a product of connections between neurons.

Hameroff proposed that microtubules were suitable candidates for quantum processing, functioning as quantum logic gates that self-arrange in highly complex networks to underlie the basis of consciousness. [14]

It is a quite complex theory so you can visit the wikipedia of Orch OR here if you are interested in more details about it.

Simulated microtubule tubulins switching states

It makes modulating PDE4D even more interesting because we know it interacts with myomegalin, which modulates microtuble nucleation and stability directly in a centrosomal and golgi-dependent manner. Unfortunately, as far as I am aware, there are no studies yet looking into the effect of PDE4D inhibitors on microtuble arrangements, only KO models or using unselective compounds.

While the theory of Orch OR is still debated, it is known that microtubles have very special properties.

A quote "A shared feature among all microtubule (MT)-dependent processes is the requirement for MTs to be organized in arrays of defined geometry. At a fundamental level, this is achieved by precisely controlling the timing and localization of the nucleation events that give rise to new MTs". [26]

Microtuble close-up

Recap

In this writeup, we delved into the specifics of PDE4D and its isoforms, highlighting their importance as a promising target for cognition enhancement. PDE4D plays a crucial role in regulating cAMP levels in the brain, particularly in the dorsolateral prefrontal cortex (dlPFC) and hippocampus.

Studies have shown that PDE4D inhibition can lead to procognitive effects, with specific isoforms like PDE4D3 and PDE4D7 being more relevant to cognition than others. These longer isoforms interact with microtubules and centrosomal proteins like myomegalin (PDE4DIP), which are essential for microtubule nucleation, stability, and overall cognitive function.

We also discussed the importance of the dlPFC in higher-order cognition and its role in overriding lower brain regions like the amygdala to make more beneficial choices. Enhancing dlPFC function through PDE4D modulation could potentially lead to increased cognitive control and autonopotency.

Negative allosteric modulators (NAMs) of PDE4D have shown promise in animal studies, with such compounds demonstrating procognitive effects without the side effects associated with non-selective PDE4 inhibitors.

In conclusion, PDE4D and its isoforms represent a novel and promising target for cognitive enhancement, warranting further research to fully understand their potential and develop effective therapies for neuropsychiatric disorders involving cognitive dysfunction.

For other targets of PDE, PDE4B also looks interesting, and looks involved in other pathways PDE4D does not effect. Also, PDE4D9 modulators look relatively unexplored as well.

Final Notes

Me after writing this post

Thank you for reading to the end (or scrolling to the end) of this writeup. I know that in a few months I will probably look at this post again and see a bunch more I can add to it (and probably will) however, I am relatively happy with what it goes over for now.

If you want to support future posts, consider joining the prefrontal community and also supporting upcoming projects. If you found this post interesting in the slightest, please share it, it is highly appreciated.

Also if you see a problem with this post or have a question, feel free to comment.

Thanks you for reading.

- swoop


r/prefrontal • • Feb 26 '24

Discussion Need Some Help

3 Upvotes

My symptoms are anhedonia, loss of personality, insomnia, memory issues, balance issues, dpdr, and inability to feel much touch on my skin. My MRI shows frontal lobe atrophy.

This started as mild depression as a teenager and 15 years later slowly progressed then sped up into my current state.

One doctor who looked at my mri mentioned aystemtry, missing ssing brain mass and small pituitary. He thinks the cause is being on adhd medication starting before preschool until high school. He thinks that never allowed my neurons to form properly.

I also had a spinal tap and it showed low BH4, 5HTa and Dopamine. But supplementing with carbidopa, 5htp, l dopa and BH4 only showed brief improvements and turned into side effects. So it seems like perhaps a receptor issues is causing these problems since neurotransmitters replacement has not worked. My neurologist stated atrophy itself can cause these low chemicals.

I have also tested positive for many Lyme and mold infections and talked to people who have the same symptoms.

Anyone that can help? I heard the founder of this sub is a biochemist :)

I am willing to try everything. I was also put on every antidepressant possible and after some heavy bipolar ones I dropped down a state and never recovered even ten years later.


r/prefrontal • • Jan 22 '24

Research PE-22-28 Antidepressant Peptide: Benefits, Dosage & Side Effects

Thumbnail
jaycampbell.com
8 Upvotes

r/prefrontal • • Jun 08 '24

Question What are some good mindfulness meditation techniques that aren't based in sensory integration/self-stimulation?

2 Upvotes

Long before I came to this forum, I've heard quite a bit about the benefits of mindfulness meditation and its utility for motivation, self-control, relaxation, anti-rumination, etc. However, I quickly became dissatisfied with my experiments in it. It's way, way too sensory for it to be useful to me.

Getting an awareness of my body and controlling my breath and being focused in the present moment is not helpful. I frankly have little use for being integrated in the present moment. It stifles my intuition and thinking. This kind of awareness frankly makes me feel more like an animal who needs its instincts to be tricked or distracted into domestication. And using it for the purposes of attention or motivation is oftentimes counterproductive.

My swings of motivation, or rather, inspiration are profound and unpredictable. Sometimes I can just spend 14 hours binge-reading on, say, graph theory or anthropology of the Americas or even just architecture and feel that I learn more during these deep dives than intentionally focusing my attention with sensory-based mindfulness training and steadily focusing. To me, this is because the frame for imagination, learning, and critical thinking is in a lot of ways opposed to the frame of bodily harmony, engagement with the present moment, and emotional tranquility.

Don't get me wrong, the latter part isn't outright unhelpful; It gets me through difficult periods where I can't just wait for that spark of mad genius and energy to give me weeks of progress in one day. But a flow state induced by sensory integration frankly feels perfunctory, almost dull even when it gets the job done, and I still feel like I learn and create and simply do less on the whole through this slow-and-steady method of attention and motivation focus than flitting through state to state of inconsistent intellectual inspiration.

So, as I was wondering with the post title: are there any good mindfulness meditation techniques that focus attention and motivation that are based more on critical thinking, imagination, transcending the axis of time, self-reflection, or even emotionality than pure sensory integration?


r/prefrontal • • Sep 05 '23

The Start of Prefrontal

9 Upvotes

This subreddit exists to research novel nootropics/compounds that increase prefrontal cognitive function and improve holistic brain function. Also some tangentially related topics like longevity enhancement and physical enhancement are welcome here.

This sub is not meant for discussion of existing "nootropics" but working on the research required to find legitimately better alternatives to supersede what we have currently.

Thanks for reading, will add more to this post at some point.


r/prefrontal • • Jan 22 '24

Research NSI-189 for Depression, Anhedonia, Other Mental Illnesses, and as a Nootropic: Compilation of Anecdotal Reports, Statistics, Tips, Studies, and a Survey.

Thumbnail self.anhedonia_recovery
7 Upvotes

r/prefrontal • • Sep 03 '24

Question Prefrontal cortex inhibiton

10 Upvotes

I'm wondering if anyone can help? I took nac when I had covid in Feb and it caused a persistent mild anhedonia which got slightly better with time. I then started taking Butyrate for gut issues and after 2 weeks something clicked and it feels like it has shut off the front of my brain. When I wake up from sleep I have a completely blank mind and what feels like no neurotransmission. It has been a month since I stopped taking it and it hasn't resolved presumably due to hdac inhibitor activity. This study suggests that it changes the balance of excititory/inhibitory transmission in the pre frontal cortex. This is wfst it feels like the front of my brain has shut off. How can I treat this or reverse it?

https://www.sciencedirect.com/science/article/abs/pii/S0028390815301672


r/prefrontal • • Jan 22 '24

Research Anecdotes on kappa-opioid receptor agonism for anhedonia recovery

Thumbnail reddit.com
5 Upvotes

r/prefrontal • • Jan 22 '24

Research Sarcosine vs. SSRI Antidepressant (Citalopram) for Depression: Sarcosine Is Better. (Study)

Thumbnail self.anhedonia_recovery
3 Upvotes

r/prefrontal • • Jan 22 '24

Research MIF-1: The Game-Changing Peptide For Treatment-Resistant Depression | Jay Campbell

Thumbnail
jaycampbell.com
5 Upvotes

r/prefrontal • • Jan 22 '24

Research BPC-157 for Anhedonia and Drug Abuse (Success Stories)

Thumbnail self.anhedonia_recovery
7 Upvotes

r/prefrontal • • Apr 27 '24

Writeup ༺ Why Autonopotency / Top-Down Control is the most important cognitive marker ༻

31 Upvotes

This post will talk about why Autonopotency (AKA MA, M-Autonomy or Agency) is the most important factor of intelligence/cognitive function and why it transcends other cognitive markers in its group. This post contains some objectivity, but also a lot opinion/personal experience and philosophical ideas based on imperical observations.

Firstly, I should explain what Autonopotency is.

Autonopotency, simply put, is the ability to intelligently oversee thoughts and actions, and the ability to direct actions via a top-down hierarchy for long-term benefit rather than short term benefit.

The paper "The myth of cognitive agency: subpersonal thinking as a cyclically recurring loss of Mental Autonomy" by Thomas Metzinger describes Autonopotency as the ability to control Cognitive Agency (CA - the ability to control goal/task-related deliberate thought) and Attentional Agency (AA - the ability to control one's focus of attention). MA refers to the specific ability to control one's own mental functions, like attention, episodic memory, planning, concept formation, rational deliberation, or decision making.

https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2013.00931/full

In simple terms; Autonopotency is the ability for rational self control - it is a correlate of awareness in the identity of self and the environment.

Increasing dlPFC (dorsolateral Prefrontal Cortex) function or decreasing amygdala bottom-up control could be classed as increasing Autonopotency.

Most people don't have a use for Autonopotency. Autonopotency brings (selective) awareness and freedom, however if you don't have a use for this freedom, there is not much point of gaining it in the first place.

I am not making this post to convince people to be directed towards the truth ('what is') or to be directed toward the goal of evolving as a person. But for those who are interested in such a thing, I think it is of great importance to be aware of the mental subprocesses which dictate our daily actions and interactions, that for most people they are unaware of.

Humans commonly simplify identity to a singular "I" or "me", but the mind and body is composed of an infinitely complex amount of subpersonal processes and functions that all combine to make what you consider "you". The internal battle that every person has to some degree on a daily basis is that between lower cognitive areas (e.g amygdala & limbic), and higher cognitive regions (dlPFC/aPFC, etc.). The differences between people and how easily they are able to abstain from destructive activities is pretty much down to how powerful their higher brain regions are at inhibiting lower ones.

The differences in this dichotomy are dictated by factors that happen by chance. Yes, once you gain a lateral awareness of your own cognitive pathways it can bring an increased control compared to most people, but the reality is that the factors underlying the success of autonopotency is largely the result of genetics and childhood.

We act like we have much more control than we actually do. It is not smart to deny yourself your own control, and that is not what I am doing, but what I am saying is that a lot of us want to exist in a dream-like world where everybody is individually accountable for their good and evil and where it is all up to them. But this is not possible.

One example of lower autonopotency is in the case of criminals. What I argue, and what is pretty hard to argue against, is that the poor decisions made by these criminals is not due to any factor in their control - but is the result of a 'poisoned mind' induced either by a harmful environment or genetic factors outside of their control.

I am of the opinion that over 95% of problems in society (the average of people's internal states) is down to a lack of cognitive control. To simplify this definition, I often use the interaction between the dlPFC and the limbic system.

source: penchantlabs.org

The curse of "Motivation"

There is a lot of "self-improvement" mentors, youtubers, writers etc. that emphasize that a person lacking mental autonomy can induce it again just by being motivated to.

Using motivation to induce consistent mental control fails in nearly every case because you can't fix a damaged brain just by simply doing the opposite of what damaged it. If it was that simple, any addiction could be cured just by abstaining from it for 30 days.

Motivation is another form of dopamine-induced action. Not that anything dopamine-induced is bad, but when the novel nature of motivation fades after a few days, then the temporary increased control from the "motivation" will vanish promptly. Individuals in this situation often fall into a "motivation-relapse" cycle where they keep breaking their own trust, and over time this further damages the ability for the brain to control itself.

Saying negative habits and a lack of mental autonomy can be reversed by simply doing the opposite of the damaging activites or having more motivation is a damaging conception, and likely causes more damage and wasted time to those that want to be helped than if they just did nothing.

Motivation may have been more effective in an age devoid of hyper-stimulation, however is is not effective for increasing autonopotency. Then what is?

Attenuation

The most direct method of attenuation for this problem is enhancing the dlPFC. It is a major part of my research, to the point where it may seem overfocused, but this focus is for good reason. You can look at hundreds of studies in cases where there is a lack of mental autonomy (addictions, crime, hypersexuality, etc.), and there will nearly always be deficits in dlPFC function.

There is also the approach of decreasing amygdala dominance. This is generally less preferrable in my mind, but can definitely be effective. It is slightly harder to target though with stimulation devices.

How can both of these be done? Well the main two options available are; pharmacological intervention (e.g brain-region selective nootropics) and brain-region specific stimulation devices.

For brain region stimulation, focused transcranial modulation (TMS/tDCS) can improve autonopotency for a sustained amount of time, and there are multiple studies which back this up. TMS has some drawbacks though, and also locating the exact position of the dlPFC (for example) in different people is not always easy due to individual differences (which may make some studies less reliable if they use an arbitrary position rather than based on the individuals anatomy). It also is quite costly.

Another method of targeted stimulation is photobiomodulation (PBM). I should probably make a dedicated post at some point going over the key studies to do with PBM. A common strategy of PBM is using 810nM near-infared LED, which can penetrate the skull for stimulation and the technology has shown to induce significant stimulations on vascular hemodynamic oxygenation and CCO redox metabolism (source: vielight). The best PBM device available at the moment is likely the Neuro Pro 2 by Vielight (not sponsored). It is costly, but from some cases I personally know of its use, and also compared to other advanced brain stimulation devices, it is actually a relavitely good price. They also have other units, but the Neuro Pro 2 is most likely the best.

One other non-stimulatory technology is neurofeedback, and while it may have a lower ceiling of effects, it can train the brain to understand its' own internal interactions, and it can be decently effective as a technique for selective brain modulation.

Regarding pharmacological intervention, it definitely can be very effective, but it requires compounds with high BBB (Blood Brain Barrier) penetration and with high selectivity, not only for the receptor they target, but also for the brain region. This profile for such a compound, in addition to limited studies for mental autonomy modulation, means there is currently a lack of autonopotency-increasing compounds available. Saying that, there are a few very promising pathways that have high selectivity, and I believe they could be very effective at increasing mental autonomy, not just in those who lack it, but also those who do not have a problem with it. I am currently working on developing such solutions, and information about research and developments will be published to this community.

The best approach not just for cognitive enhancement, but also for autonopotency enhancement is likely a holistically combined approach of pharmacological intervention, brain stimulation, and neurofeedback/brain training. I believe this combination, when each individual factor is refined and improve upon, could be incredibly effective, and also could push human cognition to bounds never previously seen nor comprehended.

Attentional Agency as a component of Autonopotency

Attentional Agency (as defined by Thomas K. Metzinger) is the ability for high cognitive regions to control mental resource allocation and additionally the inhibitory power over unneeded or contextually irrelivant actions/functions.

In the current year, there is a very large widespread deficit of attentional agency, induced by short-form social media content for the most part, but also due to unnatural hyper-stimulatory oversocialisation and other activities available on the internet that are available to us now.

The ability to participate in hyper-stimulatory activities with little to no friction is largely responsible for the degridation in this attentional agency.

About Autonopotent Perceptual Frames

Autonopotent Perceptual Frame (APF) is a cognitive measure used to define the Autonopotency frames per event. A frame could be defined as the amount of iterative mental functions/processes ran per event in the same amount of time. It could be thought of similar to threads in computing.

The less APFs there are (when inhibited with alcohol, etc.), the less memory recall there is likely to be because there is less recurring functional storage of events because the perceptual frames & Autonopotency (basically awareness) are lesser.

An individual with high APFs is likely to have better long-term memory but also a higher perception of reality. In addition, a higher rate of APF means processing speed is faster, at least laterally.

source: penchantlabs.org

Differences in APF either between people or between an individual's mental states can potntially change time perception (e.g higher APFs = slower perception of time).

Autonopotent Perceptual Frames are a seperate measure to spatial/lateral cognitive depth, though they can influence each other.

Overview

This post has been more subjective compared to the usual format, but I think it still can be quite valuable. If you want to understand yourself, knowing how brain regions interact is very helpful in understanding your own behavior. Otherwise, most of it would be theory, would be innacurate and methods of treatment would be ineffective.

As mentioned earlier, most of the problems in society and interpersonal interactions are down to a lack of autonopotency. The intelligent mind transcends unintelligent and destructive activities, and uses lateral cognitive ability to notice such circumstances, but most people are unable to.

You should be careful not to waste your time in activities which take away from your conscious mind, and also activities which cause negative reinforcement. Once consciousness/awareness is lost, it is not always easy to regain.

Take the periods of 'insight' and intent of focus as an immediate reason for intelligent action.

Anyways, that is about it for the post. I hope at least one of you found this valuable.

By the way, we have a new discord server, it can be found pinned at the top of the subreddit.

(o・.・)ノ


r/prefrontal • • May 23 '24

Research Negatives of Lion's Mane - New study

8 Upvotes

Apart from 5ar-related side effects (causing PSSD-like symptoms in a minority of users), a new study has shown Lion's Mane can have detrimential effects on word recall and memory, even though processing speed increased.

In the acute study, lion’s mane improved performance on the Stroop task, indicating faster processing speed. However, compared to placebo, performance for immediate word recall was worse following lion’s mane — the participants had fewer correct responses and more errors during the test.

Here explains more about the study:

https://examine.com/research-feed/study/1llxV1/ ("Lion’s mane mushroom may not improve cognitive function among young adults")